He is also the first ALS patient and the first non-verbal person to receive the implant, he shared in a post on X on Sunday. “I am typing this with my brain. It is my primary communication ...

Josh Cohen is co-founder and co-CEO of Amylyx. He says the company's first task was to inform several thousand ALS patients who'd been taking Relyvrio. JOSH COHEN: As hard as it is for us ...

we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS," company co-founders said in a statement.